Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 vaccine + pembrolizumab in advanced melanoma (UV1-103)
NCT03538314Phase 1Completed
- Sponsor
- Ultimovacs ASA
- Start
- Jul 2018
- Primary completion
- Oct 2022
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of UV1 in Malignant Melanoma (MM) (2 arms), sponsored by Ultimovacs ASA. Primary endpoint: Number of patients with treatment-related adverse events at 29 weeks. Started Jul 2018; status: completed.
02
Drugs
UV1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03538314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538314.